Inovio Starts Trial Testing Triple-combo Immunotherapy in Newly-diagnosed Glioblastoma – Immuno-Oncology News
Immuno-Oncology News |
Inovio Starts Trial Testing Triple-combo Immunotherapy in Newly-diagnosed Glioblastoma
Immuno-Oncology News Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor may now enroll in a Phase 1b/2a clinical trial testing a triple immunotherapy combination for the cancer. Inovio Pharmaceuticals is leading the study to evaluate its T-cell … |
